Keyword: AstraZeneca

Despite being one of the lowest-paid pharma CEOs, Pascal Soriot says defeating a Pfizer takeover was right for AstraZeneca.

With data showing Farxiga can reduce hospitalizations for heart failure or CV deaths against placebo, AZ plans to seek a label update.

Merck halves Keytruda's price in China; Takeda eyes selling Shire's Xiidra and Natpara; another ex-GSK scientist pleads guilty to trade secret theft.

AZ struck out in May in trying to expand Fasenra into COPD. But it does have new long-term data that could bolster the drug in its current indication.

AstraZeneca’s latest data on its triple-combination COPD candidate may not do much to help it against rival GlaxoSmithKline.

The CD22-directed cytotoxin treatment is AstraZeneca's second approved blood cancer asset, with peak sales estimated at about $500 million.

GSK's Nucala took a big hit Friday when the FDA stiff-armed its hoped-for new approval in COPD, which could have boosted sales significantly.

It hasn’t been an easy summer for AstraZeneca in the respiratory department, but the British drugmaker has finally come up with a win.

Sanofi and the Securities and Exchange Commission entered a $25 million civil settlement over bribery allegations in the Middle East.

A group of pediatric experts has recommended injected vaccines over AstraZeneca's FluMist for the upcoming season.